Skip to main content

PFIZER INC

For the period ended Mar 30, 2025. Filed May 5, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 30, 2025 · Filed May 5, 2025

PFE$29.36+0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Comprehensive Income

Three Months Ended
(MILLIONS)March 30,2025March 31,2024
Net income before allocation to noncontrolling interests$2,973$3,123
Foreign currency translation adjustments, net(557)140
Unrealized holding gains/(losses) on derivative financial instruments, net(123)217
Reclassification adjustments for (gains)/losses included in net income(a)(313)(12)
(436)205
Unrealized holding gains/(losses) on available-for-sale securities, net(31)(51)
Reclassification adjustments for (gains)/losses included in net income(b)155(14)
124(65)
Reclassification adjustments related to amortization of prior service costs and other, net(30)(28)
Reclassification adjustments related to curtailments of prior service costs and other, net(33)—
(64)(28)
Other comprehensive income/(loss), before tax(932)251
Tax provision/(benefit) on other comprehensive income/(loss)(191)53
Other comprehensive income/(loss) before allocation to noncontrolling interests$(741)$198
Comprehensive income/(loss) before allocation to noncontrolling interests$2,232$3,321
Less: Comprehensive income/(loss) attributable to noncontrolling interests43
Comprehensive income/(loss) attributable to Pfizer Inc.$2,229$3,319

(a)Reclassified into Other (income)/deductions—netand Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions—net.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.